Madrigal announces additional positive results from the pivotal phase 3 maestro-nash clinical trial of resmetirom for the treatment of nash with liver fibrosis

Conshohocken, pa., jan. 06, 2023 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today announced additional results from the pivotal phase 3 maestro-nash biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist. the new maestro-nash data are being presented at the nash-tag conference, taking place from january 5-7, 2023 in park city, utah.
MDGL Ratings Summary
MDGL Quant Ranking